Company Spotlight: Neurxstem

Can you share the story behind Neurxstem Inc.? What inspired you to found the company, and what unique challenges in neuroscience or regenerative medicine are you aiming to solve?

I have spent most of my professional life as a professor and a scientific investigator in a medical school setting. While the experience was exciting exploring basic science questions building on established science, it lacked opportunity to do high-risk research for worthy medical applications in the real world.

I was a volunteer raising funds for Autism. I took a risk supported by a philanthropic donation to make human brain models in a dish to find a rigorous scientific way to address autism etiology at a molecular level.

I founded Neurxstem Inc. precisely to engage in such interdisciplinary research in precision brain medicine after inventing stem cell derived human brain models that were highly advanced with all brain regions from the retina to the spinal cord and BBB in a single entity, replicable and also showed construct validity for human brain diseases. A US patent was obtained for this invention. This invention generates the 'big data' that is precise, accurate, and robust and needed for our latest advances in developing highly reliable AI Health agents for predictive analytic applications in brain medicine.

Neurxstem is pioneering work in stem cell-based therapies for neurological disorders. What breakthroughs or innovations have you achieved so far, and how do you see these impacting patients and the broader healthcare landscape?

“A New Era for Brain Health Has Begun.”

Using its patented human brain model platform, NNOP™, Neurxstem is delivering the world’s first lab-based tools that accurately replicate the root causes of major human brain diseases, providing a new path toward early detection, prevention, and intervention.

Breakthroughs Announced by Neurxstem

• Alzheimer’s Disease - Genetic susceptibility markers, environmental toxins and nutritional deficiencies have been identified as major contributors. Preventive nutrition and novel therapies have shown early promise, as do targeted drugs, some repurposed.

• Parkinson’s Disease - Genetic susceptibility markers, environmental toxins and nutritional deficiencies have been identified as major contributors. Novel therapeutic targets have been identified.

• Autism - Early research links exposure to toxins (like lead and pesticides) and nutrient imbalances to increased autism risk. Neurxstem has identified potential genetic susceptibility markers.

• Ageing - A new “Progeria brain model” developed by Neurxstem mirrors the neural gene networks and hallmarks of human brain ageing, opening doors to better understanding and drugs and diets which have the potential of to slow cognitive decline.

The life sciences industry is often faced with challenges in securing funding for early-stage innovation. How has Neurxstem navigated these hurdles, and what advice would you give to other entrepreneurs seeking investment in cutting-edge technologies?

Neurxstem has successfully sought capital to advance its innovation to the market using personal funds initially and then by competing for capital from federal grants.

Call for Action: A Health Partnership

Neurxstem is now actively seeking a public-private partnership and joint ventures with government agencies, Pharma companies, corporations and investors to save lives, and reduce the massive economic and social burden caused by these conditions to:

• Scale and validate these scientific breakthroughs

• Develop population-level early diagnostic tools

• Provide preventive nutrition and health guidelines

• Deliver cost-effective, non-invasive interventions for at-risk communities

Looking ahead, what do you see as the biggest opportunities for growth and innovation in the life sciences investment space, particularly in areas like neuroscience and regenerative medicine?

Why It Matters: Human and Economic Impact

• Alzheimer’s disease costs the U.S. over $150 billion annually in caregiving alone

• Parkinson’s disease is the second most prevalent neurodegenerative disease

• Autism affects 1 in 36 children in the U.S., with annual costs exceeding $60 billion

• Opioid addiction is a national emergency with devastating effects on families and defense readiness

• Aging populations are straining healthcare systems globally

As a leader in the life sciences field, what role do you think events like the LSX Investival Showcase play in fostering collaboration, innovation, and investment? How can platforms like this help companies like Neurxstem thrive?

The LSX Investival Showcase allows avant-garde precision medicine companies like Neurxstem to present their innovative solutions to vexing problems in brain health by creating high value opportunities and avenues to foster collaborations, public-private partnership and joint ventures with government agencies, Pharma companies, corporations and investors.

Find out more at: www.neurxstem.com